AbCellera Biologics Inc. (8QQ)
XSTU 
Summary
8QQ Chart
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why
ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Jacqueline Kisa - TD Securities Puneet Souda - Leerink Partners LLC Malcolm Hoffman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Good afternoon, and welcome to AbCellera's First Quarter 2025 Business Update and Conference Call. My name is Jasmine, and I will facilitate the audio portion of today's interactive broadcast.
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.14 per share a year ago.
AbCellera Biologics Inc. Dividends
AbCellera Biologics Inc. Earnings
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Feb 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Feb 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
AbCellera Biologics Inc. (8QQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AbCellera Biologics Inc. ever had a stock split?
AbCellera Biologics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Carl L.G. Hansen Ph.D. CEO | XSTU Exchange | CA00288U1066 ISIN |
| CA Country | 596 Employees | - Last Dividend | - Last Split | 11 Dec 2020 IPO Date |
Overview
AbCellera Biologics Inc. is a pioneering entity in the biotechnology sector, focusing on revolutionizing the approach towards antibody drug discovery and development. The company leverages a unique engine that harnesses the power of natural immune responses to discover antibodies. This innovative platform is not only capable of identifying these vital antibodies but also pre-enriches them, streamlining the path from discovery to development. Since its inception in 2012, AbCellera has established itself as a key player in the biotech industry, forming strategic alliances with prominent companies like Eli Lilly, Confo Therapeutics, and Biogen Inc. These collaborations aim to accelerate the discovery of therapeutic antibody candidates across various medical conditions, including metabolic and endocrine disorders, atopic dermatitis, and neurological conditions. Headquartered in Vancouver, Canada, AbCellera continues to push the boundaries of medical science, charting new territories in antibody discovery and drug development.
Products and Services
AbCellera Biologics Inc. offers a range of preclinical products and services aimed at tackling some of the most challenging conditions in the medical field today. The company's expertise in antibody discovery and development has enabled the inception of several promising preclinical candidates, along with strategic partnerships focused on advancing therapeutic solutions.
- ABCL635 - This preclinical product is designed to address metabolic and endocrine conditions. Leveraging AbCellera's antibody discovery engine, ABCL635 represents a significant step forward in the treatment of diseases that affect millions of people worldwide.
- ABCL575 - Focused on atopic dermatitis, ABCL575 emerges from the company's platform as another testament to its innovative approach towards treating complex skin conditions. This product embodies AbCellera's commitment to providing relief to those afflicted by atopic dermatitis.
In addition to these preclinical products, AbCellera's strategic collaborations underline its role as a versatile partner in the drug discovery process:
- Eli Lilly and Company: A research collaboration and license agreement focused on the development of antibody-based therapies. This partnership highlights AbCellera's capability in bringing its discovery engine to bear on large-scale pharmaceutical development projects.
- Confo Therapeutics: This research collaboration is aimed at discovering therapeutic antibody candidates targeting two undisclosed GPCR targets. It showcases AbCellera's adaptability in exploring new therapeutic areas and potential targets.
- Biogen Inc.: A strategic collaboration with Biogen underscores AbCellera's expansion into neurological conditions, leveraging its antibody discovery and development expertise to tackle some of the most pressing challenges in neurology.
Contact Information
